Marta S. F.
- Country
- Spain
- Department
- Ophthalmology
Research Overview
- Efficacy of Topical Somatostatin (COLIRIOBCN070660) in Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy: A Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Ranibizumab Port Delivery System Refill Regimens in Neovascular Age-Related Macular Degeneration: A Phase IIIb Randomized Study
- Long-term Safety Evaluation of GT005 in Geographic Atrophy Secondary to Age-related Macular Degeneration Post Antecedent Gyroscope Study
Data & Insights
Has run more than one trial at 86 of 145 partner sites.
Specializations
Geographic atrophy and dry age-related macular degeneration
The investigator is involved in clinical research focused on geographic atrophy secondary to age-related macular degeneration, with attention to preserving retinal structure and slowing lesion progression. The portfolio also includes studies in dry AMD with geographic atrophy, reflecting a strong interest in advanced degenerative macular disease.
- Geographic atrophy progression
- Dry AMD with GA
- Retinal degeneration
Research activity in this area includes long-term evaluation of emerging retinal therapies aimed at stabilizing disease burden in patients with established macular damage.
Neovascular age-related macular degeneration
Another major therapeutic focus is neovascular age-related macular degeneration, with studies addressing visual outcomes, disease control, and sustained treatment delivery. This includes work centered on maintaining best-corrected visual acuity and supporting longer-acting treatment strategies for wet AMD.
- Wet AMD
- Visual acuity preservation
- Long-acting ocular treatment approaches
The investigator’s trial portfolio in this field reflects sustained involvement in therapies designed to improve disease management in chronic exudative retinal disease.
Diabetic retinopathy
The investigator also participates in research on diabetic retinopathy, particularly non-proliferative diabetic retinopathy and microaneurysm burden in patients with advanced retinal vascular disease. This area highlights interest in early retinal vascular intervention and prevention of progression.
- Non-proliferative diabetic retinopathy
- Microaneurysm reduction
- Retinal vascular disease
These studies place emphasis on retinal disease control in diabetes-related eye complications within an ophthalmology setting.
Gene therapy and ocular biologics
A substantial part of the research landscape involves gene therapy and other biologic approaches for retinal disease, including programs targeting complement-mediated mechanisms and sustained intraocular treatment delivery. The investigator’s work spans innovative ocular therapies intended to address both degenerative and neovascular retinal conditions.
- Complement pathway targeting
- Intravitreal biologics
- Retinal gene-based treatment
This area includes ongoing interest in therapies designed for durable disease modification in macular disorders.
Port delivery and long-term retinal treatment safety
The investigator is engaged in studies evaluating port delivery system strategies and long-term safety monitoring for sustained retinal therapy. These trials focus on treatment durability, tolerability, and extended follow-up in chronic neovascular AMD and geographic atrophy.
- Port delivery system
- Long-term safety
- Tolerability in chronic retinal disease
Research in this domain supports innovation in continuous ocular drug delivery and extended clinical management of macular disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.